Table 1 Patient characteristics at initiation of gemcitabine and nab-paclitaxel
Age, years | 61 (50–74) |
Sex, no (%) | |
Male | 11 (39.3 %) |
Female | 17 (60.7 %) |
Disease, no (%) | |
Metastatic | 23 (82.1 %) |
Locally advanced | 5 (17.9 %) |
ECOG performance status, no (%) | |
≤1 | 27 (96.4 %) |
≥2 | 1 (3.6 %) |
Median no of FOLFIRINOX cycles (range) | 12 (5–46) |
Median interval from last FOLFRINOX to initiation of G + Nab-P, weeks (range) | 5.4 (1.7–40.3) |
N = 28 | |